Patients and carers

  • Email
  • Help

Information for you

On this page, you will find information on the Agency’s activities that are most relevant to patients and carers, including news, and events.

You can contribute to the Agency’s work by responding to public consultations.

Learn more about how Patients and carers are actively involved in the work of the Agency.

Featured information

  • patients_leaflet

    Enabling science that works for patients

    A new leaflet by EMA shows how the work of the Agency benefits patients in the European Union (EU).  The leaflet explains how EMA collaborates closely with patients to understand their point of view and to make sure that new medicines address their needs.

  • Public hearing on valproate

    EMA will hold a public hearing on 26 September 2017 on the safety of valproate-containing medicines in the treatment of women and girls who are pregnant or of childbearing age. The Agency has published guidance on the process and practical arrangements, including how to participate either as a speaker or an observer. EMA has also made an information video. To register your interest in taking part, send us a filled application form by 25 August. 

  • Patients_consumers_annual_report

    2016 annual report of interactions

    EMA has published the 2016 annual report on its interactions with patients, consumers and healthcare professionals, incorporating both quantitative and qualitative data. For previous reports, see Key documents.

  • Clinical data website survey

    EMA has launched a survey on its clinical data website to collect users’ views on the content and usability of the website. EMA launched the website on 20 October 2016 in line with EMA’s policy on the publication of clinical data (Policy 0070). The survey should take less than 10 minutes to complete and user feedback will contribute to further developing EMA’s transparency policies as well as to improving the website. Start the survey

  • Personalised medicine

    EMA held a workshop in March 2017 on the challenges and opportunities for personalised medicines and the role of patients and healthcare professionals. The workshop discussed policy developments in Europe and globally, the contribution of the European medicines regulatory network and how clinical practice and public participation can support personalised medicine. EMA will publish the presentations, video recording and a workshop report on the event page.

News for patients and carers

Events of interest

  • 15/03/2017


    EMA Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting

    This joint PCWP/HCPWP meeting discusses the European Medicines Agency's 2016 annual report, its interactions with patients, consumers, healthcare professionals and their organisations, its work plans for 2018/19, the outcome of the Committee for Medicinal Products for Human Use pilot project, European Antibiotic Awareness Day. It also provides an update on topic groups including biosimilars, the 10 year report on conditional marketing authorisations, regulators’ and health technology assessment bodies’ related activities and feedback from the scientific committees. ... Read more

  • 27/03/2017 - 28/03/2017


    Committee for Herbal Medicinal Products (HMPC): 27-28 March 2017

    The Committee on Herbal Medicinal Products (HMPC) is the committee that is responsible for preparing the Agency’s opinions on questions relating to herbal medicines. ... Read more

  • 29/05/2017 - 30/05/2017


    Committee for Herbal Medicinal Products (HMPC): 29-30 May 2017

    The Committee on Herbal Medicinal Products (HMPC) is the committee that is responsible for preparing the Agency’s opinions on questions relating to herbal medicines. ... Read more

  • 13/11/2017 - 14/11/2017


    Second paediatric strategy forum on medicine development for mature B cell malignancies in children

    This second multi-stakeholder paediatric strategy forum, jointly organised by ACCELERATE and the European Medicines Agency, will focus on mature B cell malignancies (lymphoma and leukaemia) in children. The goal of this meeting is to share information, in a pre-competitive setting, which will inform a paediatric drug development strategy and subsequent decisions and facilitate the developments of innovative medicines for the treatment of children with mature B cell malignancies. Participation is restricted and on invitation only. Interested parties, including patients and parent-representatives, academia, clinicians and industry, should express their interest. For clinicians and researchers, priority will be given to those who have expertise and experience in clinical trials for mature B cell malignancies in children or intend to design such studies in the future. ... Read more

  • 12/06/2017 - 13/06/2017


    EMA/FDA/Health Canada joint workshop addressing unmet needs of children with pulmonary arterial hypertension

    This joint workshop organised the European Medicines Agency (EMA), the United States Food and Drug Administration (FDA) and Health Canada brings together experts and stakeholders to discuss requirements for the development of medicines in paediatric pulmonary arterial hypertension (PAH) and to address the need of the current paediatric clinical practice in a timely manner. The objectives are to improve the understanding of problems related to the conduct of clinical trials in the paediatric population, refine endpoints and study design to address the clinical trials challenges in this rare paediatric population, set priorities in future research in the field of pharmacokinetics and pharmacodynamics measurements and post-marketing tools in paediatric PAH medicines and provide medicine developers with more guidance specific to global product development which takes into account current limitations. ... Read more

  • See all Events of interest

Information for:

Find information for...

FAQ spotlight